Phil Febbo

Dr. Febbo, 53, has served as CMO at Illumina since 2018 and is responsible for developing and executing the Company's medical strategy to drive genomic testing into healthcare practice in order to improve health outcomes. Prior to joining Illumina, he served as CMO of Genomic Health for five years where he drove the company's medical strategy, was accountable for the development of evidence supporting GHI's proprietary tests, engaged with the payer community to drive reimbursement, and served as a corporate officer between 2016 and 2018. Prior to Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. He currently serves on the board of the American College of Medical Genetics and Genomics Foundation.